<SEC-DOCUMENT>0001193125-21-032411.txt : 20210208
<SEC-HEADER>0001193125-21-032411.hdr.sgml : 20210208
<ACCEPTANCE-DATETIME>20210208163550
ACCESSION NUMBER:		0001193125-21-032411
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210208
FILED AS OF DATE:		20210208
DATE AS OF CHANGE:		20210208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		21601903

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d109312d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>For the month of February 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39530</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ImmunoPrecise Antibodies Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3204 -4464
Markham Street, Victoria, British Columbia V8Z 7X8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F &#9744; Form <FONT STYLE="white-space:nowrap">40-F</FONT> &#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d109312dex991.htm">News Release dated February&nbsp;8, 2021 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>IMMUNOPRECISE ANTIBODIES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;8, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Lisa Helbling</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lisa Helbling</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d109312dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g109312g71z78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VICTORIA, British Columbia, February&nbsp;8, 2021<B> </B>&#150; IMMUNOPRECISE ANTIBODIES LTD. (the &#147;Company&#148; or &#147;IPA&#148;) (NASDAQ: IPA / TSX
VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, it has closed its previously announced public offering (the &#147;Offering&#148;) of 1,616,293 common shares of the Company (the
&#147;Common Shares&#148;), at a price to the public of $13.45 per Common Share, less underwriting discounts and commissions, for gross proceeds to the Company of approximately $21.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co. acted as sole book-running manager for the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has granted to the underwriter a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 242,443 Common Shares
at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from the Offering for (i)&nbsp;pursuing the Company&#146;s objective of expanding its operations into Good Laboratory Practice and
Good Manufacturing Practice-certified; (ii)&nbsp;the development and commercialization of Talem Therapeutics, LLC&#146;s, a wholly owned subsidiary of the Company, internal and partnered therapeutic discovery programs; (iii)&nbsp;investments in
employees, partnerships, cloud computing, data curation and analysis to enable further work toward the development of custom algorithms, cloud computing, large-scale sequence data analysis, and expanded access to next-generation sequencing
technologies; (iv)&nbsp;the development of its PolyTope<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> approach to the development of innovative therapeutics and vaccines against the <FONT STYLE="white-space:nowrap">COVID-19;</FONT> and
(v)&nbsp;general corporate and working capital purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Offering, the Company filed with the securities regulatory authorities in
each of the provinces of Canada (except Quebec), a short form base shelf prospectus dated December&nbsp;11, 2020. The short form base shelf prospectus was filed on Form <FONT STYLE="white-space:nowrap">F-10</FONT> with the U.S. Securities and
Exchange Commission (&#147;SEC&#148;). The Company also filed a final prospectus supplement to the short form base shelf prospectus with the securities regulatory authority in the Province of British Columbia as well as with the SEC as part of a
registration statement on Form <FONT STYLE="white-space:nowrap">F-10</FONT> under the U.S.-Canada multijurisdictional disclosure system (&#147;MJDS&#148;). The Common Shares were only offered and sold in the United States either directly or through
duly registered U.S. broker dealers. No Common Shares were offered or sold to Canadian purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made in the United States only by
means of the registration statement, including the base shelf prospectus and applicable prospectus supplement. Such documents contain important information about the Offering.. Copies of the short form base shelf prospectus and accompanying final
prospectus supplement have been filed with the SEC and are available for free on the SEC&#146;s website at www.sec.gov and on the SEDAR website at www.sedar.com. Electronic copies of the final prospectus supplement and registration statement may
also be obtained from H.C. Wainwright&nbsp;&amp; Co., LLC, 430 Park Avenue 3rd Floor, New York, NY 10022, or by calling (646) <FONT STYLE="white-space:nowrap">975-6996</FONT> or by emailing placements@hcwco.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities regulatory authority has either approved or disapproved the contents of this news release. This news release shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities
laws of any such province, state or jurisdiction.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ImmunoPrecise Antibodies Ltd. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPA is a global technology platform company with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> solutions
empowering companies to discover and develop therapies against any disease. The Company&#146;s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic.
IPA&#146;s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact
solutions@immunoprecise.com.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains forward-looking statements and forward-looking information within the meaning of applicable United States securities laws and
Canadian securities laws (together, the &#147;forward-looking statements&#148;. Forward-looking statements are often identified by the use of words such as &#147;plans&#148;, &#147;expects&#148; or &#147;does not expect&#148;, &#147;is
expected&#148;, &#147;estimates&#148;, &#147;intends&#148;, &#147;anticipates&#148; or &#147;does not anticipate&#148;, or &#147;believes&#148;, or variations of such words and phrases or state that certain actions, events or results
&#147;may&#148;, &#147;could&#148;, &#147;would&#148;, &#147;might&#148; or &#147;will&#148; be taken, occur or be achieved. Forward-looking statements contained in this news release include, but are not limited to, statements relating to the
Offering, including the use of proceeds from the Offering. In respect of the forward-looking statements contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be
reasonable at the time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release.
Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements
contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral,
that may be made from time to time by us or on our behalf, except as required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOURCE ImmunoPrecise Antibodies Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fr&eacute;d&eacute;ric Chabot, Phone: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-438-863-7071,</FONT></FONT></FONT> Email: frederick@contactfinancial.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g109312g71z78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109312g71z78.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !F G # 2(  A$! Q$!_\0
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M7*SQMT:-V1U*NI(8'L:TO#VKG1]361B?(D^24>WK^%;/C;1O)F&I0K\DAVS
M=F['\:Y*O1BU4@>+*,J%3T-+XO\ A475JGB*Q7<\2A;G;_$G\+_AT^A]J\?K
MZ%\(:G'J%A)I%Z!)M0A5;D/&>"OX?RKQGQIX8D\*^(9K/!-L_P"\MG/\2'M]
M1TKGC>+Y&>FI*I%31V_P>\6!2_AV]?Y6R]H6Z>K)_4?C7,_$GPG_ ,(SX@:6
MWCQI]Z3)#@<(W\2?AU'L?:N4MKB:SN8KBVD,<T+AXW'56'(->\Q?8OBEX!"R
M,L4[8#$#)@G7OCT_H:F7N2YNA:]Y6.'^$?A+^T]3.M7<>;6S;$(8</+Z_P#
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M?:MY245=G+3A*<N6/4S-!(_MZR_ZZBNX\6:V^E6"QP'%Q/D*?[H[FMB*T@@
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M>*4>8O&3<JG)V%BM9YP6A@ED ZE$) _*HB,$@@@CJ#7L-M;QVL"0PH$C084
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M_P#0S7H_P._X^-8_W8_ZUYQK7_(=U'_KZE_]#->C_ [_ (^-8_W8_P"M:3^
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MT^:*\C".TNX ,#Q@>E%><7#1AA*<XU+M&_1117$>J%%%% !7GOCF-$UR-E4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
